Tumor-treating fields fail to extend OS in advanced ovarian cancer
Click Here to Manage Email Alerts
The addition of tumor-treating fields to chemotherapy did not prolong survival for women with platinum-resistant ovarian cancer, according to the device’s manufacturer.
Tumor-treating fields [TTFields (Novocure)] are electric fields that are utilized to exert physical forces to kill cancer cells.
Image: Adobe Stock
They are delivered by a noninvasive, portable device approved in the United States for treatment of glioblastoma or mesothelioma.
The randomized phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial included 558 women with platinum-resistant ovarian cancer.
Researchers assigned 280 of them to paclitaxel plus TTFields. The other 278 received paclitaxel alone.
The study failed to meet its primary endpoint, as results showed no statistically significant improvement in OS among women assigned TTFields (median, 12.2 months vs. 11.9 months; HR = 1.008).
TTFields exhibited a safety profile consistent with prior studies.
The trial enrolled women who had received up to five prior lines of systemic therapy. An exploratory analysis suggested a possible survival benefit for women who had received only one prior line of therapy.
“While the final results of the ENGOT-ov50/GOG-3029/INNOVATE-3 trial differ from our initial expectation, these data add important context to the treatment paradigm,” David O’Malley, MD, professor of obstetrics and gynecology at The Ohio State University Wexner College of Medicine and director of the division of gynecologic oncology at The James Comprehensive Cancer Center, said in a Novocure-issued press release. “We see treatment exposure and number of prior therapies are relevant and can drive outcomes, and we will leverage these data as we explore and identify new opportunities to treat this deadly disease.”
Read more about
Click Here to Manage Email Alerts